What clinical trials has Arazlo (tazarotene) been studied in?
Arazlo’s clinical development program included trials in people with acne and trials designed to assess skin tolerability and dosing in disorders where topical tazarotene is used. The program focused on whether applying tazarotene to the skin improves outcomes compared with control, while tracking typical topical retinoid effects such as irritation.
Which outcomes did the Arazlo trials measure?
Across Arazlo studies, endpoints typically included improvements in lesion counts for acne and measures of symptom control or skin response, along with safety/tolerability outcomes (for example, irritation or dryness), which are common concerns with topical retinoids.
What side effects did participants report in Arazlo trials?
Topical tazarotene trials generally report local skin reactions consistent with retinoids—commonly redness, dryness, burning/stinging, and irritation. Trial safety data also track rates of discontinuation due to side effects.
Are there different Arazlo strengths or dosing regimens tested?
Clinical studies for topical tazarotene products typically explore regimen details such as starting frequency and whether patients can tolerate escalation. These regimen elements are usually designed to balance efficacy with irritation risk.
Where can I find trial details (study identifiers, publications, and results)?
For a deeper paper trail—such as study identifiers and trial-specific details—check the prescribing information and the underlying regulatory summaries, which compile the clinical study record for Arazlo.
If you tell me the condition you mean (acne vs. another labeled indication) and whether you want phase-by-phase trials (Phase 1/2/3) or specific NCT numbers, I can narrow it to the most relevant Arazlo studies.
Sources
No sources were provided in the prompt to cite specific Arazlo trial names, phases, or results.